Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis
Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI tr...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ling Liang [verfasserIn] Janice, Y Kung [verfasserIn] Bradley Mitchelmore [verfasserIn] Jasmine Gill [verfasserIn] Andrew Cave [verfasserIn] Hoan Linh Banh [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Übergeordnetes Werk: |
In: Journal of Pharmacy & Pharmaceutical Sciences - Canadian Society for Pharmaceutical Sciences, 2016, 24(2021) |
|---|---|
| Übergeordnetes Werk: |
volume:24 ; year:2021 |
| Links: |
|---|
| DOI / URN: |
10.18433/jpps31632 |
|---|
| Katalog-ID: |
DOAJ064206599 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ064206599 | ||
| 003 | DE-627 | ||
| 005 | 20230309034830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18433/jpps31632 |2 doi | |
| 035 | |a (DE-627)DOAJ064206599 | ||
| 035 | |a (DE-599)DOAJb1d10adacdfb4578b57e92846187349b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 050 | 0 | |a RS1-441 | |
| 100 | 0 | |a Ling Liang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment. | ||
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 700 | 0 | |a Janice, Y Kung |e verfasserin |4 aut | |
| 700 | 0 | |a Bradley Mitchelmore |e verfasserin |4 aut | |
| 700 | 0 | |a Jasmine Gill |e verfasserin |4 aut | |
| 700 | 0 | |a Andrew Cave |e verfasserin |4 aut | |
| 700 | 0 | |a Hoan Linh Banh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Pharmacy & Pharmaceutical Sciences |d Canadian Society for Pharmaceutical Sciences, 2016 |g 24(2021) |w (DE-627)242663869 |w (DE-600)1422972-9 |x 14821826 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2021 |
| 856 | 4 | 0 | |u https://doi.org/10.18433/jpps31632 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/b1d10adacdfb4578b57e92846187349b |z kostenfrei |
| 856 | 4 | 0 | |u https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31632 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1482-1826 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2021 | ||
| author_variant |
l l ll y k j yk ykj b m bm j g jg a c ac h l b hlb |
|---|---|
| matchkey_str |
article:14821826:2021----::nitnicnetnezmihbtrnuecuhnhnsptetaytm |
| hierarchy_sort_str |
2021 |
| callnumber-subject-code |
RM |
| publishDate |
2021 |
| allfields |
10.18433/jpps31632 doi (DE-627)DOAJ064206599 (DE-599)DOAJb1d10adacdfb4578b57e92846187349b DE-627 ger DE-627 rakwb eng RM1-950 RS1-441 Ling Liang verfasserin aut Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment. Therapeutics. Pharmacology Pharmacy and materia medica Janice, Y Kung verfasserin aut Bradley Mitchelmore verfasserin aut Jasmine Gill verfasserin aut Andrew Cave verfasserin aut Hoan Linh Banh verfasserin aut In Journal of Pharmacy & Pharmaceutical Sciences Canadian Society for Pharmaceutical Sciences, 2016 24(2021) (DE-627)242663869 (DE-600)1422972-9 14821826 nnns volume:24 year:2021 https://doi.org/10.18433/jpps31632 kostenfrei https://doaj.org/article/b1d10adacdfb4578b57e92846187349b kostenfrei https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31632 kostenfrei https://doaj.org/toc/1482-1826 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 24 2021 |
| spelling |
10.18433/jpps31632 doi (DE-627)DOAJ064206599 (DE-599)DOAJb1d10adacdfb4578b57e92846187349b DE-627 ger DE-627 rakwb eng RM1-950 RS1-441 Ling Liang verfasserin aut Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment. Therapeutics. Pharmacology Pharmacy and materia medica Janice, Y Kung verfasserin aut Bradley Mitchelmore verfasserin aut Jasmine Gill verfasserin aut Andrew Cave verfasserin aut Hoan Linh Banh verfasserin aut In Journal of Pharmacy & Pharmaceutical Sciences Canadian Society for Pharmaceutical Sciences, 2016 24(2021) (DE-627)242663869 (DE-600)1422972-9 14821826 nnns volume:24 year:2021 https://doi.org/10.18433/jpps31632 kostenfrei https://doaj.org/article/b1d10adacdfb4578b57e92846187349b kostenfrei https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31632 kostenfrei https://doaj.org/toc/1482-1826 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 24 2021 |
| allfields_unstemmed |
10.18433/jpps31632 doi (DE-627)DOAJ064206599 (DE-599)DOAJb1d10adacdfb4578b57e92846187349b DE-627 ger DE-627 rakwb eng RM1-950 RS1-441 Ling Liang verfasserin aut Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment. Therapeutics. Pharmacology Pharmacy and materia medica Janice, Y Kung verfasserin aut Bradley Mitchelmore verfasserin aut Jasmine Gill verfasserin aut Andrew Cave verfasserin aut Hoan Linh Banh verfasserin aut In Journal of Pharmacy & Pharmaceutical Sciences Canadian Society for Pharmaceutical Sciences, 2016 24(2021) (DE-627)242663869 (DE-600)1422972-9 14821826 nnns volume:24 year:2021 https://doi.org/10.18433/jpps31632 kostenfrei https://doaj.org/article/b1d10adacdfb4578b57e92846187349b kostenfrei https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31632 kostenfrei https://doaj.org/toc/1482-1826 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 24 2021 |
| allfieldsGer |
10.18433/jpps31632 doi (DE-627)DOAJ064206599 (DE-599)DOAJb1d10adacdfb4578b57e92846187349b DE-627 ger DE-627 rakwb eng RM1-950 RS1-441 Ling Liang verfasserin aut Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment. Therapeutics. Pharmacology Pharmacy and materia medica Janice, Y Kung verfasserin aut Bradley Mitchelmore verfasserin aut Jasmine Gill verfasserin aut Andrew Cave verfasserin aut Hoan Linh Banh verfasserin aut In Journal of Pharmacy & Pharmaceutical Sciences Canadian Society for Pharmaceutical Sciences, 2016 24(2021) (DE-627)242663869 (DE-600)1422972-9 14821826 nnns volume:24 year:2021 https://doi.org/10.18433/jpps31632 kostenfrei https://doaj.org/article/b1d10adacdfb4578b57e92846187349b kostenfrei https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31632 kostenfrei https://doaj.org/toc/1482-1826 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 24 2021 |
| allfieldsSound |
10.18433/jpps31632 doi (DE-627)DOAJ064206599 (DE-599)DOAJb1d10adacdfb4578b57e92846187349b DE-627 ger DE-627 rakwb eng RM1-950 RS1-441 Ling Liang verfasserin aut Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment. Therapeutics. Pharmacology Pharmacy and materia medica Janice, Y Kung verfasserin aut Bradley Mitchelmore verfasserin aut Jasmine Gill verfasserin aut Andrew Cave verfasserin aut Hoan Linh Banh verfasserin aut In Journal of Pharmacy & Pharmaceutical Sciences Canadian Society for Pharmaceutical Sciences, 2016 24(2021) (DE-627)242663869 (DE-600)1422972-9 14821826 nnns volume:24 year:2021 https://doi.org/10.18433/jpps31632 kostenfrei https://doaj.org/article/b1d10adacdfb4578b57e92846187349b kostenfrei https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31632 kostenfrei https://doaj.org/toc/1482-1826 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 24 2021 |
| language |
English |
| source |
In Journal of Pharmacy & Pharmaceutical Sciences 24(2021) volume:24 year:2021 |
| sourceStr |
In Journal of Pharmacy & Pharmaceutical Sciences 24(2021) volume:24 year:2021 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Therapeutics. Pharmacology Pharmacy and materia medica |
| isfreeaccess_bool |
true |
| container_title |
Journal of Pharmacy & Pharmaceutical Sciences |
| authorswithroles_txt_mv |
Ling Liang @@aut@@ Janice, Y Kung @@aut@@ Bradley Mitchelmore @@aut@@ Jasmine Gill @@aut@@ Andrew Cave @@aut@@ Hoan Linh Banh @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
242663869 |
| id |
DOAJ064206599 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ064206599</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309034830.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.18433/jpps31632</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ064206599</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJb1d10adacdfb4578b57e92846187349b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ling Liang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Janice, Y Kung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bradley Mitchelmore</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jasmine Gill</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrew Cave</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hoan Linh Banh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Pharmacy & Pharmaceutical Sciences</subfield><subfield code="d">Canadian Society for Pharmaceutical Sciences, 2016</subfield><subfield code="g">24(2021)</subfield><subfield code="w">(DE-627)242663869</subfield><subfield code="w">(DE-600)1422972-9</subfield><subfield code="x">14821826</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2021</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.18433/jpps31632</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/b1d10adacdfb4578b57e92846187349b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31632</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1482-1826</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2021</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Ling Liang |
| spellingShingle |
Ling Liang misc RM1-950 misc RS1-441 misc Therapeutics. Pharmacology misc Pharmacy and materia medica Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis |
| authorStr |
Ling Liang |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)242663869 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RM1-950 |
| illustrated |
Not Illustrated |
| issn |
14821826 |
| topic_title |
RM1-950 RS1-441 Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis |
| topic |
misc RM1-950 misc RS1-441 misc Therapeutics. Pharmacology misc Pharmacy and materia medica |
| topic_unstemmed |
misc RM1-950 misc RS1-441 misc Therapeutics. Pharmacology misc Pharmacy and materia medica |
| topic_browse |
misc RM1-950 misc RS1-441 misc Therapeutics. Pharmacology misc Pharmacy and materia medica |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of Pharmacy & Pharmaceutical Sciences |
| hierarchy_parent_id |
242663869 |
| hierarchy_top_title |
Journal of Pharmacy & Pharmaceutical Sciences |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)242663869 (DE-600)1422972-9 |
| title |
Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis |
| ctrlnum |
(DE-627)DOAJ064206599 (DE-599)DOAJb1d10adacdfb4578b57e92846187349b |
| title_full |
Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis |
| author_sort |
Ling Liang |
| journal |
Journal of Pharmacy & Pharmaceutical Sciences |
| journalStr |
Journal of Pharmacy & Pharmaceutical Sciences |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| author_browse |
Ling Liang Janice, Y Kung Bradley Mitchelmore Jasmine Gill Andrew Cave Hoan Linh Banh |
| container_volume |
24 |
| class |
RM1-950 RS1-441 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ling Liang |
| doi_str_mv |
10.18433/jpps31632 |
| author2-role |
verfasserin |
| title_sort |
angiotensin-converting enzyme inhibitor induced cough in chinese patients: a systematic review and meta-analysis |
| callnumber |
RM1-950 |
| title_auth |
Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis |
| abstract |
Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment. |
| abstractGer |
Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment. |
| abstract_unstemmed |
Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| title_short |
Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis |
| url |
https://doi.org/10.18433/jpps31632 https://doaj.org/article/b1d10adacdfb4578b57e92846187349b https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31632 https://doaj.org/toc/1482-1826 |
| remote_bool |
true |
| author2 |
Janice, Y Kung Bradley Mitchelmore Jasmine Gill Andrew Cave Hoan Linh Banh |
| author2Str |
Janice, Y Kung Bradley Mitchelmore Jasmine Gill Andrew Cave Hoan Linh Banh |
| ppnlink |
242663869 |
| callnumber-subject |
RM - Therapeutics and Pharmacology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.18433/jpps31632 |
| callnumber-a |
RM1-950 |
| up_date |
2024-07-03T21:43:39.987Z |
| _version_ |
1803595829731131392 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ064206599</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309034830.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.18433/jpps31632</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ064206599</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJb1d10adacdfb4578b57e92846187349b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ling Liang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Angiotensin-Converting Enzyme Inhibitor Induced Cough in Chinese Patients: a Systematic Review and Meta-analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose: To determine the risk of angiotensin converting enzyme inhibitor (ACEI)-induced cough compared to non-ACEI cough among Chinese patients. Methods: A comprehensive search was conducted including randomized controlled trials, case-control studies and observational studies that compared ACEI treatment with control treatment in MEDLINE, EMBASE, CINAHL, Scopus, Google Scholar and ProQuest Dissertations & Theses Global. The studies which contained: Chinese population, ACEI, non-ACEI, and indications for the treatment of ACEI were included. The pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the relative risk of cough between ACEIs and non-ACEI drugs based on the events of reported cough in each study. Results: Eleven randomized controlled trials were included with a total of 1815 patients. The total number of cough events in ACEI treatment was 101 in 930 patients (11%) and 20 in 885 patients (2%) in the Non-ACEI treatment. The pooled RR was 5.16 (95% CI: 3.39-7.85) under fixed model. The discontinuation number of single ACEI treatment due to coughing side effect was 21 and the withdrawal rate was 4.13%. Only two patients discontinued non-ACEIs treatment due to the intolerable cough and the withdrawal rate was 0.34%. The overall RR of withdrawal related to cough was 7.06 (95% CI: 2.49-20.04). Conclusions: The pooled risk of the incidence of ACEI-induced cough was about five times higher than that of non-ACEI-induced cough in Chinese population. The risk of withdrawal events related to cough in the single ACEI treatment was seven times of that in the non-ACEI treatment.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Janice, Y Kung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bradley Mitchelmore</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jasmine Gill</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrew Cave</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hoan Linh Banh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Pharmacy & Pharmaceutical Sciences</subfield><subfield code="d">Canadian Society for Pharmaceutical Sciences, 2016</subfield><subfield code="g">24(2021)</subfield><subfield code="w">(DE-627)242663869</subfield><subfield code="w">(DE-600)1422972-9</subfield><subfield code="x">14821826</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2021</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.18433/jpps31632</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/b1d10adacdfb4578b57e92846187349b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31632</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1482-1826</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2021</subfield></datafield></record></collection>
|
| score |
7.401886 |